TAGAMET PREVENT TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

CIMETIDINE

Disponible des:

MEDTECH PRODUCTS INC

Codi ATC:

A02BA01

Designació comuna internacional (DCI):

CIMETIDINE

Dosis:

200MG

formulario farmacéutico:

TABLET

Composición:

CIMETIDINE 200MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

OTC

Área terapéutica:

HISTAMINE H2-ANTAGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0111925005; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2023-04-06

Fitxa tècnica

_ _
_Page 1 of 24_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
TAGAMET® PREVENT
Cimetidine Tablets
Tablet, 200 mg, Oral
USP
Histamine H
2
– Receptor Antagonist
ATC Code: A02BA01
Medtech Products Inc.
660 White Plains Rd., Suite 250
Tarrytown, NY 10591
USA
Date of Initial Authorization:
Apr 12, 2000
Date of Revision:
Mar 22, 2023
Submission Control Number: 270508
_ _
_ _
_Page 2 of 24_
RECENT MAJOR LABEL CHANGES
None.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
....................................................... 5
4.5
Missed Dose
...........................................................................................................
5
5
OVERDOSAGE
................................................